Company news
Sarepta Therapeutics, Inc. news in 2020
Sarepta Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Sarepta Therapeutics Announces Executive Management Changes
December 13, 2020
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
December 6, 2020
Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
December 3, 2020
Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
November 24, 2020
Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020
November 19, 2020
Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
November 4, 2020
Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
November 4, 2020
Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
November 1, 2020
Sarepta Therapeutics to Announce Third Quarter 2020 Financial Results and Recent Corporate Developments on November 5, 2020
October 28, 2020
Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
September 27, 2020
Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration
September 27, 2020
Long-term functional data from Sarepta Therapeutics’ Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World Muscle Society
September 13, 2020
Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
September 8, 2020
Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
August 24, 2020
Sarepta Therapeutics and University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic Diseases
August 10, 2020
Sarepta Therapeutics Announces Second Quarter 2020 Financial Results and Recent Corporate Developments
August 4, 2020
Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020
July 28, 2020
Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
July 23, 2020
Sarepta Therapeutics Launches “Rare Lessons” Program to Promote Greater Diversity and Inclusion in the Classroom and Support Awareness of Rare Diseases
July 14, 2020
Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase
July 1, 2020
Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer
June 29, 2020
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
June 25, 2020
Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases
June 21, 2020
Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology
June 14, 2020
Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E
June 7, 2020
Sarepta Therapeutics to Share Clinical Update from SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
June 4, 2020
Sarepta Therapeutics to Present at the 2020 RBC Capital Markets Virtual Global Healthcare Conference
May 11, 2020
Sarepta Therapeutics and Dyno Therapeutics Announce Agreement to Develop Next-Generation Gene Therapy Vectors for Muscle Diseases
May 10, 2020
Sarepta Therapeutics Announces First Quarter 2020 Financial Results and Recent Corporate Developments
May 5, 2020
Sarepta Therapeutics to Announce First Quarter 2020 Financial Results and Recent Corporate Developments on May 6, 2020
April 28, 2020
Sarepta Therapeutics Announces Research Agreement with U.S. Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as Treatments for COVID-19
April 27, 2020
Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program
February 26, 2020
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments
February 25, 2020
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments on February 26, 2020
February 18, 2020
Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors
January 12, 2020
Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 5, 2020
Decks in 2020
- Technical Presentation (June 2020)
Technical · 37 slides · Jun 8, 2020
- J.P. Morgan 38th Annual Healthcare Conference (January 2020)
Conference · 36 slides · Jan 13, 2020
- Technical Presentation (2020)
Technical · 10 slides · 2020